IN-CUMMINS-INC.
22.9.2022 09:57:25 CEST | Business Wire | Press release
Cummins Inc. (NYSE: CMI) is showcasing its platform of zero-emissions technologies this week at the IAA Transportation show, the world's largest mobility show, in Hannover, Germany. A range of new Cummins technologies and the recently acquired Meritor ePowertrain technologies are available publicly together for the first time. With over a century of experience as a global power leader, Cummins is solidifying its commitment to providing comprehensive zero-emissions technology on a global scale.
"Cummins has deep application expertise, and we are uniquely positioned to deliver solutions that truly fit the needs of commercial applications," said Amy Davis, Vice President and President of New Power at Cummins. "Realizing a net-zero future will require a range of technologies. Our extensive zero-emissions portfolio is how we will meet varied customer demands across the hardest-to-abate industries and make the energy transition possible."
One key zero-emissions product Cummins revealed at IAA is its fourth-generation hydrogen fuel cell engine. Designed to meet the duty-cycle, performance and packaging requirements of medium- and heavy-duty trucks and buses, the fuel cell technology is available in 135 kW single and 270 kW dual modules.
Scania in Europe and Daimler Trucks North America have each announced collaborations with Cummins to develop and integrate these next-generation fuel cell engines into demonstrator vehicles. The systems use fourth-generation variable pressure technology to provide higher power density, power nodes and operating temperatures for easier system integration into vehicles. They also have strong operating cycle efficiency and durability for a lower total cost of ownership.
“We know our customers have diverse needs and complicated duty cycles to support, which is why we focus on continued innovation and improvement,” said Amy Adams, Vice President of Fuel Cell and Hydrogen Technologies at Cummins. “We’re developing hydrogen fuel cell technology that demonstrates the capacity and flexibility required to meet or exceed the power needs for on-highway commercial vehicles – proving hydrogen as a viable solution to decarbonize the economy.”
Attendees at IAA will also get the first glimpse of a drivetrain assembled with a newly introduced Cummins lithium iron phosphate (LFP) battery pack, Meritor’s 17xe ePowertrain and Meritor’s Power Control and Accessory System (PCAS). Cummins recently added the ePowertain and PCAS solutions to its portfolio through its acquisition of Meritor. The ePowertrain leverages market-leading technologies in the axle, motor and inverter, delivering performance, efficiency and packaging advantages at a competitive cost. Additionally, the PCAS provides power where needed and control of necessary sub-systems while reducing packaging size and simplifying integration.
Cummins is adding an LFP battery to its line of lithium-ion battery products to expand support of electrified commercial vehicle applications. The LFP solution gives customers access to faster charging and longer-life batteries, targeting the medium-duty truck and school bus markets. By using a multi-chemistry strategy, Cummins is positioned to expand its manufacturing capacity further and diversify its supply chain, providing customers with more cost-effective electrification solutions.
"We are giving customers options to enable them to adapt to a zero-emissions future faster," said Brian Wilson, General Manager of Electrified Components at Cummins. "With the recent acquisition of Meritor and our new multi-chemistry approach, we will be able to tailor our solutions and offer a one-stop-shop for customers' powertrain needs."
Cummins' portfolio includes four batteries, each of which targets a different duty cycle and use case and complement each other. In addition to the LFP option, this includes three nickel manganese cobalt (NMC) batteries – the BP95E, BP74E and BP30E. The BP95E is Cummins’ next-generation solution that prioritizes greater energy density in applications for customers who need more weight-sensitive solutions or have longer ranges. The BP30E is ideal for meeting limited-space applications and rugged demands, and the BP74E is the foundation for Cummins’ BEV innovation and progress.
Download Cummins product photos.
About Cummins Inc.
Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains, and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, electric power generation systems, batteries, electrified power systems, hydrogen generation and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 59,900 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment, and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $2.1 billion on sales of $24.0 billion in 2021. See how Cummins is powering a world that is always on by accessing news releases and more information at https://www.cummins.com/always-on.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005980/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
